About half of the familial breast cancer cases are found to bear mutations in the breast cancer susceptibility gene 1 (BRCA1). The majority of BRCA1 mutations produce a truncated protein and BRCA1-associated breast tumors exhibit a number of defined tumor phenotypes. The function of BRCA1 has been examined in gene knockout mice in which the nullizygous mice die early in utero, but this lethality can be partially rescued by a nullizygous p53 mutation. Wild-type BRCA1 protein binds to a number of cellular proteins, including DNA repair protein Rad51, tumor suppressor p53, RNA polymerase II holoenzyme, RNA helicase A, CtBP-interacting protein, c-myc, BRCA1-associated RING domain protein (BARD1), BRCA2 protein, etc. These proteins likely mediate the involvement of BRCA1 in DNA repair, transcriptional transactivation, and cell cycle control. Overall, BRCA1 protein may act as a converging vehicle for cell regulatory proteins to associate with. Therefore, mutations in BRCA1 may affect the composition of these complexes on which dysregulation of cellular functions with eventual development of malignancy is expected.
Introduction
Approximately one in eight to ten women living in Western countries will develop breast cancer during their lifetime (Casey, 1997) . The etiology of sporadic breast cancer, which accounts for about 95% of total cases, still remains largely unknown. The remaining cases are familial breast cancer that is hereditary in nature. There is hope that by discovering the genes conferring susceptibility to familial breast cancer and determining their mechanisms of action, we may better understand the etiology and progression of breast tumors.
The first breast cancer susceptibility gene discovered, BRCA1, spans approximately 100 kb on chromosome 17q21.3, from which a 7.8 kb mRNA is transcribed that encodes a protein of 1863 amino acids (Miki et al., 1994) . Mutations within BRCA1 account for about 45% of hereditary breast cancers as well as 80 to 90% of hereditary combined breast and ovarian cancers (Couch et al., 1997) . These high values are currently being re-evaluated since the families used in these studies may not be representative of all breast cancer families (Blackwood and Weber, 1998) . Surprisingly, mutations in the BRCA1 gene have not been associated with sporadic breast cancer; nevertheless, mutations and loss of heterozygosity are found in a small number of sporadic ovarian cancers (Merajver et al., 1995) . Since mutations in BRCA1 predispose the carriers to breast and ovarian cancers, and the loss of the wildtype allele is often found in tumors, BRCA1 is regarded as a tumor suppressor.
Recent research has begun to unravel how BRCA1 may perform its tumor suppressor function. The entire BRCA1 protein shows no homology with any known protein (Miki et al., 1994) . However, several functional motifs in the BRCA1 protein have been defined, including a RING finger domain, a carboxy-terminal domain known as BRCT, and binding sites for tumor suppressor p53 and DNA repair protein Rad51 (see Table 1 ). Each domain interacts with specific protein(s) pivotal for distinct cellular processes ( Figure 1 ). It is likely that the BRCA1 protein exerts its control over cellular functions by acting as a platform for these proteins to converge and interact, and may therefore create interactive modes for regulating their respective functions.
Mutation Spectrum and Phenotypes of BRCA1-associated Breast Cancers
An analysis of BRCA1-associated tumors reveals that tumors positive for BRCA1 mutations are more likely to be of ductal type, histological grade III, and show heavier lymphocyte infiltration than either sporadic breast cancer or non-BRCA1 hereditary breast cancer . Moreover, BRCA1-associated tumors are more often negative for estrogen receptor, progesterone receptor and c-erb-2. DNA non-diploidy and higher S-phase fraction values are also observed more often in BRCA1-associated breast cancers (Marcus et al., 1996) , as well as a low frequency of lymph-node metastasis (Eisinger et al., 1998) . The observation that BRCA1-associated tumors display unique histological and biological features is compatible with the interpretation that these tumors are under distinct genetic control. Gayther et al. (1995) assessed the effects of mutation location on phenotypic expression at the disease level. A significant correlation was observed between the position of a BRCA1 mutation and the ratio of breast to ovarian cancer incidence within families. Specifically, mutations located upstream of exon 13 are more likely to give a higher proportion of ovarian cancer, whereas the opposite is observed for mutations 3Ј to this exon. Several possible models could explain this trend, including alternative splicing of the 3Ј end in breast and ovarian cells, allowing for the presence of ovarian transcripts unaffected by the mutation. However, experimental evaluations of these models have yet to be published.
A second genotype/phenotype relationship is that BRCA1 mutations at the 5Ј-or 3Ј-ends of the coding region correlate with highly proliferative tumors (Sobol et al, 1996) . It suggests that inactivation of known functional domains of the BRCA1 protein, such as the RING finger or BRCT domain, results in a more severe phenotype than mutations occurring elsewhere.
A first hint of the function of BRCA1 may be revealed by the spectrum of BRCA1 mutations found in familial breast cancer patients. Since the discovery of the BRCA1 gene (Miki et al., 1994) , at least 215 unique coding region mutations have been identified as currently listed in the Human Gene Mutation Database. Of these, 118 (54.9%) are micro-lesions, represented by 85 small deletions and 31 small insertions. Nucleotide substitutions account for 89 (41.4%) mutations, with 74 missense/nonsense mutations and 15 mutations resulting in aberrant splicing. Gross deletions make up the remaining 8 (3.7%) mutation sites. It is important to note that more than 80% of known mutations result in a truncated form of the BRCA1 protein (Couch et al., 1997) . The relatively low number of point mutations found in BRCA1 suggests that a significant portion of the encoded protein has to be inactivated to confer susceptibility to breast cancer. Most of the tumor-associated point mutations are found in conserved domains such as the RING finger and the BRCT domain.
An overview of BRCA1 mutation positions shows no obvious signs of clustering or mutational hotspots. However, a more in-depth analysis reveals that certain sequences and nucleotides of BRCA1 may be more susceptible to mutations than others (Rodenhiser et al., 1996) . Examination of the DNA region in the immediate area of 53 out of 74 known BRCA1 mutations shows the presence of repeated motifs, including strings of homonucleotides, short direct repeats and inverted repeats. For example, the mutation 185delAG prevalent in Ashkenazi Jews precedes a second AG pair (TCTTAGAGTGTC) (Struewing et al., 1995) . The association of repeat regions with mutation sites in BRCA1 is similar to findings in other tumor suppressor genes such as p53, Rb and NF1. The generation of these repeat region-associated mutations may be explained by Streisinger's model (1966) of slippage and misalignment in DNA replication.
The accumulation of somatic defects in BRCA1-associated breast cancer differs from that of sporadic breast cancer (Tirkkonen et al., 1997) . On average, BRCA1-associated tumors show a higher number of genetic changes than control tumors, which may be reflective of the role of BRCA1 in DNA repair (Gowen et al., 1998) . Specifically, BRCA1-associated tumors more often display chromosomal loss at 5q, 4q22-qter, 4p, 13q, 2q22-q34, 12q14-q21 and Xq21-qter than controls. It is expected that these regions contain loci the loss of which promotes cancer progression in carriers of a BRCA1 mutation. Further studies are necessary to pinpoint the exact genes that are crucial for BRCA1-associated tumorigenesis. Several groups have already analyzed the p53 protein status in BRCA1 tumors. Rhei et al. (1998) reported that 24 of 29 BRCA1-as- sociated ovarian tumors studied contained p53 mutations, suggesting that the p53 mutation is not an absolute requirement in BRCA1 cancers. However, the activities of the wild-type p53 protein can be modified by numerous factors, thus a lack of mutation in this gene does not necessarily imply normal functioning.
Embryonic Lethality in Brca1 Knockout Mice
In view of the fact that defects in BRCA1 predispose women to breast and ovarian cancer, a gene knockout mouse is an obvious tool to investigate the role that BRCA1 may play in development and in tumorigenesis. Mice homozygous for a Brca1 mutation in which either exon 2, exons 5 and 6, or exon 11 are deleted die in utero. Mice heterozygous for these mutations exhibit normal phenotypes and do not develop tumors (Hakem et al., 1996; Gowen et al., 1996; Liu et al., 1996; Ludwig et al., 1997) . Brca1 5 -6 homozygotes do not survive past E7.5 of gestation, and show an abnormal organization of cell layers. By E6.5, about the time of gastrulation, cellular proliferation is significantly impaired in comparison to normal embryos, while the amount of cells undergoing apoptosis is similar for both wild-type and mutant embryos. At the molecular level, the Brca1 5 -6 knockout mouse results in the abnormal expression of at least two cell-cycle genes. Decreased mRNA levels of the p53-inhibitor mdm2 are observed, as well as an increase in the cdk-inhibitor p21 (Hakem et al., 1996) . These findings may explain why mutant embryos display impaired cellular proliferation. In this model, low levels of mdm2 allow p53 expression to be upregulated, subsequently activating p21 transcription. Increased p21 levels would then cause cell cycle arrest in the G1 phase, leading to an overall reduction in proliferation. This hypothesis is supported by the finding that Brca1 5 -6 and Brca1 2 knockout mice show increased survival in a p53 -/-background Ludwig et al., 1997) . These mice display more developmental advances than their Brca1 -mediated lethality .
Although nullizygous Brca1 mice die in utero with involvement of p53 and p21, there is one case report of a woman with germline mutations in both BRCA1 alleles (Boyd et al., 1995) . Each allele shows a deletion of two adenines (AA 2800 ) with an expected protein product of 900 amino acids. Her risk of disease manifestation does not appear any different from that of BRCA1 heterozygotes, as she developed breast cancer at the age of 32. On the other hand, BRCA1 heterozygous women are often small for their gestational age as compared with their unaffected relatives (Jernstrom et al., 1998) , suggesting a role of BRCA1 in human fetal development. However, the adult heights of these women are within normal range.
A Role of BRCA1 in DNA Repair
The investigation of the fundamental nature of BRCA1 protein function has led to several lines of evidence implicating BRCA1 in DNA repair (Table 1) . First, the BRCA1 protein colocalizes in S phase nuclear foci with the DNArepair protein hRAD51 (Scully et al., 1997a) . Colocalization of BRCA1 and hRAD51 is also observed on developing synaptonemal complexes during meiosis. hRAD51 shares significant homology with bacterial RecA, which mediates the pairing and ATP-dependent exchange of DNA strands in recombination (Ivanov and Haber, 1997) . Second, hRAD51 interacts with a specific region of BRCA1 (amino acids 758 -1064) (Scully et al., 1997a) . It is clear that following UV-or hydroxyurea-induced DNA damage in S phase MCF7 cells both BRCA1 and hRad51, as well as the BRCA1-associated RING domain protein (BARD1), disperse from nuclear foci and relocate to regions of damaged, replicating DNA (Scully et al., 1997b) . Importantly, these areas of non-duplex DNA are sites of proliferating cell nuclear antigen (PCNA) activity, and colocalization of BRCA1, hRAD51, and BARD1 with PCNA subsequent to DNA damage allows speculation on the presence of a multi-protein DNA-repair complex involving at least these four proteins. PCNA functions in post-replication repair in Saccharomyces cerevisiae along with RAD6, RAD18 and DNA polymerase ␦ (Torres- Ramos et al., 1996) , and may perform a similar role in mammalian cells through the involvement of daughter strand gap repair (Svetlova et al., 1998) . This hypothesis is supported by the finding that staurosporine, a protein kinase inhibitor (and thus an inhibitor of PCNA and BRCA1 activation), blocks post-replication repair in cells deficient in nucleotide excision repair. Further, PCNA foci observed in UV-irradiated, nucleotide excision repair-deficient cells overlap with the pattern of newly replicated chromatin. These results implicate BRCA1 in post-replication repair following DNA damage.
The most direct evidence of the involvement of BRCA1 in DNA repair is based on the finding that mouse embryonic stem cells nullizygous for Brca1 are defective in their ability to carry out transcription-coupled repair of oxidative DNA damage, a process in which DNA damage is repaired more rapidly in transcriptionally active DNA than other genomic DNA. These cells are also hypersensitive to ionization radiation and hydrogen peroxide. These results suggest that Brca1 participates, directly or indirectly, in transcription-coupled repair of oxidative DNA damage in embryonic stem cells (Gowen et al., 1998) . Further, BRCA1, through its BRCT-transactivation domain, binds to RNA polymerase II via RNA helicase A (Anderson et al., 1998) , thereby linking BRCA1 to the multi-protein complex required for transcription-coupled repair.
In fact, a close relationship exists between DNA repair and transcription (Friedberg, 1996) . It is also notable that hRAD51 and other repair proteins associate with RNA polymerase II (Maldonado et al., 1996) . Moreover, it is known that defects in DNA repair disrupt development (Snow, 1997) , therefore providing another hint on the em- Anderson et al. (1998) ; (2) Chen et al. (1998) ; (3) Hsu and White (1998) ; (4) Jensen et al. (1998) ; (5) Jin et al. (1997) ; (6) Ouchi et al. (1998) ; (7) Scully et al. (1997b) ; (8) Scully et al. (1997a) ; (9) Scully et al. (1997c) ; (10) Wang et al. (1997) ; (11) Wang et al. (1998) ; (12) Wu et al. (1996) ; (13) Yu et al. (1998) ; (14) Zhang, H., et al. (1998). bryonic lethality observed in Brca1 nullizygous mice. Interestingly, the morphology and time-line of Brca1 5 -6 knockout mice resemble rad51 knockout mice (Lim and Hasty, 1996; Tsuzuki et al., 1996) . Mice that are rad51 -/-display the same proliferation incapability and time of embryonic death as Brca1 5 -6 mutants. In addition, rad51
-/-mice grown in a p53 -/-background show increased survival time (Lim and Hasty, 1996) similar to Brca1
The presumptive role of BRCA1 as a caretaker of the genome would predict that the BRCA1-associated breast cancer exhibits impaired DNA repair capacity with an increased sensitivity to radiation therapy (Kinzler and Vogelstein, 1997) . In a retrospective study of 30 breast cancer patients with BRCA1 mutations, a normal acute reaction to radiotherapy and a similar prognosis when compared to sporadic breast cancer patients were observed (Gaffney et al., 1998) . This lack of increased sensitivity to radiotherapy in BRCA1-associated tumors in this initial study cannot be immediately reconciled with the role of BRCA1 in DNA repair. Further studies with an expanded patient group are required to evaluate this important prediction.
Transcriptional Transactivation by BRCA1 and Its BRCT Domain
The last 217 amino acids of BRCA1 are conserved among at least 50 other proteins, including p53-binding protein 1 (p53BP1), RAD9, three eukaryotic DNA ligases, and a wide range of other proteins involved in gene regulation and DNA repair (Callebaut and Mornon, 1997; Bork et al., 1997) . This homologous region was designated BRCT (BRCA1 C-terminus) domain. It consists of two repeated motifs of non-identical stretches of amino acids, with the second motif ending eight amino acids shy of the carboxyterminus. The BRCT motif has been found to occur singly or in multiple copies in other proteins. The structure and fold of a single BRCT motif from the human DNA repair protein XRCC1 has been determined through X-ray crystallography at 3.2 Å resolution (Zhang, X. et al., 1998) . It comprises a four-strand parallel beta-sheet surrounded by three alpha-helices, which form an autonomously folded domain. Based on this structure, a model for a single BRCT motif of BRCA1 has been constructed. Several chain-termination BRCA1 mutations associated with human familial breast tumors are predicted to encode proteins that fold incorrectly.
The high acidity of the BRCA1-BRCT domain led to the demonstration that it can activate transcription of reporter genes when fused to a yeast GAL4 DNA binding domain (Monteiro et al., 1996; Chapman and Verma, 1996) . Furthermore, some of the BRCA1 mutations found in BRCA1-associated breast cancers abolish transcriptional activity in this assay, implying that the loss of transcriptional transactivation by BRCA1 may be involved in tumorigenesis. Ouchi et al. (1998) showed that BRCA1 is a p53-dependent transcriptional activator for the murine mdm2 and human p21
Waf1 promoters. BRCA1 also acts as a p53-dependent transcriptional activator of the bax promoter . Mutations in the BRCT domain of BRCA1 result in the loss of transcriptional activation, as shown by a C-terminal deletion mutant of BRCA1 lacking the last 94 amino acids exhibiting just 8% of wild-type transcriptional activity (Ouchi et al., 1998) . These studies suggest that at least one role for BRCA1 is that of a transactivational coactivator of p53. Alternatively, BRCA1 can also activate transcription in the absence of p53, as demonstrated by the activation of the p21 Waf1 genomic promoter in p53-inactive SW480 cancer cells (Somasundaram et al., 1997) . BRCA1 and p53 physically interact in vitro and in vivo as demonstrated by co-immunoprecipitation experiments ( Table 1) . Deletion of an N-terminal region of exon 11 of BRCA1 (amino acids 224 -500) impairs in vitro interaction with p53. A truncation mutant of BRCA1 that retains the p53 binding site exhibits a dominant negative phenotype for p53-dependent transcription, therefore further substantiating the important role of interaction of BRCA1 and p53 in vivo .
A complicated relationship exists between BRCA1 and other proteins involved in cell cycle control and DNA repair. Treatment of MCF7 cells with either UV light or adriamycin, a topoisomerase II inhibitor and p53 inducer, reduces BRCA1 mRNA and protein levels (Andres et al., 1998) . However, MCF7 cells containing a dominant-negative p53 mutant require over ten-fold higher dosages of adriamycin to engender the same effect, suggesting that p53 is a regulator of BRCA1 expression. The reduction of BRCA1 mRNA and protein levels subsequent to UV or adriamycin treatment may allow cells with damaged DNA to undergo repair before apoptosis ensues.
The BRCT domain-mediated biological function is not limited to mammalian cells, but can also exert its activity in yeast, where homologs for BRCA1 and p53 are absent. S. cerevisiae cells transformed with either full-length BRCA1 or with pAD-BRCA1, a GAL4 transcriptional activation domain/SV40 T antigen NLS/BRCA1 fusion construct, form smaller colonies than controls (Humphrey et al., 1997) . Deletion mutants of pAD-BRCA1 retaining the BRCT domain also show the small colony phenotype. Importantly, the small colony phenotype is abrogated by the introduction of known human BRCA1 BRCT-domain mutations, while neutral polymorphisms and mutations falling outside of the BRCT region have no effect on colony size.
A mechanism of BRCA1 transactivation has been supported by the finding that BRCA1 interacts with RNA polymerase II as well as hSRB7, first identified in yeast as suppressor mutant, and the basal transcription factors TFIIF, TFIIE and TFIIH in HeLa cell extracts (Scully et al., 1997c) . A deletion of the last 11 amino acids of BRCA1 reduces its association with the RNA polymerase II holoenzyme, suggesting that the C-terminus is important for this interaction (Table 1) .
Further details of the interaction mechanism are reported by Anderson et al. (1998) and demonstrate that BRCA1 interacts with RNA polymerase II via a linkage with RNA helicase A (RHA) (Table 1) , a protein with homology to maleless in Drosophila which increases expression of Xchromosomal genes in males. Three RHA binding domains were identified within the BRCT domains of BRCA1: amino acids 1650 -1700, 1701 -1750 and 1751 -1800. Of the three domains the first binds RHA with less affinity than the other two. The RHA protein itself contains domains which bind to the Creb binding protein (CRB), RNA polymerase II, and the newly identified domain (amino acids 230 -323) which binds to BRCA1. It is possible that BRCA1 interacts with DNA-bound transcription factors to mediate a signal to RNA Pol II via RHA (Anderson et al., 1998) . This finding also provides an opportunity for crosstalk with the transcription-coupled repair of oxidative DNA damage (Gowen et al., 1998) .
The BRCT domain of BRCA1 is also implicated in transcriptional repression (Yu et al., 1998) . Using the Sos recruitment system, a new form of two-hybrid screening, the BRCT domain of BRCA1 was shown to interact in vivo with the CtB interacting protein (CtIP). CtIP is a protein associated with the CtBP transcriptional co-repressor, a tumor suppressor first shown to bind to E1A (Boyd et al., 1993) as well as transcriptional repression domains of three Drosophila transcription factors (Nibu et al., 1998; Poortinga et al., 1998) . The interaction between BRCT and CtIP is completely ablated by three tumor associated mutations in the BRCT domain (Table 1 ). It will be of interest to investigate whether the CtIP association can modulate the transactivation of cell cycle regulatory genes, such as p21 and bax.
Potential Cell Cycle Control by BRCA1 and BRCA1-Associated RING Domain Protein, BARD1
The near amino-terminal end of BRCA1 contains a RING finger domain of 43 amino acids that is 100% conserved between BRCA1 proteins of mouse and human (Abel et al., 1995) . Brzovic et al. (1998) showed that the first 110 amino acids of the BRCA1 protein, which contain the RING finger, comprise a unique, protease resistant structural domain that forms homodimers in solution. Breast cancer associated mutations within the RING finger domain of BRCA1 have been reported, including C61G, C64G, and an 11 bp deletion at the end of exon 2, which marks the beginning of the RING domain (Castilla et al., 1994 , Friedman et al., 1994 , Miki et al., 1994 . The RING finger domain of BRCA1 binds zinc ions at two sites, and analysis of the C61G mutation in the context of an N-terminal BRCA1 construct reveals a loss of zinc binding at site II (Brzovic et al., 1998) . As a consequence, the mutant proteins aggregate into oligomers and the resistance to proteolysis is compromised.
Although some RING finger proteins are known to mediate transcription, the BRCA1 RING finger domain does not bind DNA or polyribonucleotides and is not known to possess a transactivation function. However, a RING finger is also a structural motif for protein-protein interaction (Table 1) . Through yeast two-hybrid analysis, the BRCA1-associated RING-domain protein (BARD1) from human cells was discovered as a novel protein which interacts with BRCA1 (Wu et al., 1996) . The human BARD1 protein contains a RING finger domain, three tandem ankyrin repeats and two BRCT motifs. Interestingly, the BRCT domain of BARD1 is shorter than that of BRCA1 and the translational stop codon occurs right before the equivalent of tyrosine 1853 of BRCA1, an amino acid known to be mutated to a stop codon in some breast cancer patients (Friedman et al., 1994) . The interaction of BARD1 and BRCA1 occurs at the N-terminus of both proteins, and most likely involves the RING domain of both proteins (Wu et al., 1996) . The unique N-terminal structural domain found in both BRCA1 and BARD1, which includes the RING finger, is capable of mediating both homodimerization and BRCA1/BARD1 heterodimerization in solution (Brzovic et al., 1998) .
Evidence for a BRCA1/BARD1 interaction also stems from immunofluorescence localization studies which show that both proteins colocalize to S phase nuclear dots or foci (Jin et al., 1997 , Scully et al., 1997b . Neither BRCA1 nor BARD1 form nuclear foci in G1, suggesting an aggregation of both proteins just before S phase. Interestingly, whereas BRCA1 protein expression is low or absent in G1 and peaks before S phase, BARD1 shows a constant steady-state level throughout the entire cell cycle. How BARD1 and BRCA1 come to form nuclear foci, or whether one requires the other to do so, remains unanswered. Moreover, immunostaining for BARD1 and Rad51 shows that these two proteins also localize to PCNA nodules after hydroxyurea or UV treatment (Scully et al., 1997b) . It therefore seems possible that BRCA1, BARD1, Rad51 and PCNA exist in a multi-protein complex at some time after DNA damage, though the existence of such a complex has yet to be shown.
The importance of the recently discovered BARD1 protein is highlighted also by the discovery of three BARD1 mutations in primary breast, ovarian and uterine cancers (Hao Thai et al., 1998) . In the cases of the breast and uterine tumors, each mutation is somatic and localized to the BRCT domain. The ovarian cancer patient, however, has a germline mutation of BARD1 (Gln564Arg) with loss of the wild-type allele in malignant ovarian cells. These data raise the possibility of a direct tumor suppressing function for BARD1.
The mouse homolog of BARD1 shows significant sequence conservation to human BARD1 at the RING finger domain, the ankyrin repeats and the BRCT domain (Ayi et al., 1998) . To assess the biological role of Bard1, IrmingerFinger et al. (1998) expressed antisense or ribozyme constructs to murine Bard1 in TAC-2 cells (Soriano et al., 1995) , a derivative of a normal murine mammary gland epithelial cell line (NMuMG). An increase in cell size, flattening of cells, enlarged nuclei of which up to 30% were multilobed or multinuclear, and loss of contact inhibition in some clonal cell lines were observed. Analysis of asynchronous cultures of these antisense or ribozyme expressing cells showed a significant increase of G1 phase along with a reduction of S and G2/M phases as compared to controls, indicating that a reduction of the Bard1 level results in an accumulation of cells in G1 phase. Further, TAC-2 cells stably transfected with antisense or ribozymes to Bard1, displayed an abnormal DNA content versus cell size ratio. Whereas non-transfected cells formed distinct G1 and G2/M populations of 2N and 4N, respectively, transfected cells formed a diffuse population of approximately 4N, as well as one group of cells with a DNA content of 8N. These studies suggest that a normal level of Bard1 is essential in maintaining the progression of the cell cycle. Since BARD1 is capable of forming heterodimers with BRCA1, this study further implicates another avenue for BRCA1 to modulate the cell cycle, in addition to the transactivation of cell cycle related genes through its BRCT-domain.
Within the context of the cell cycle, BRCA1 mRNA levels increase late in G1 phase and remain relatively high until the end of G2 phase (Vaughn et al., 1996; Gudas et al., 1996) . This accumulation of BRCA1 mRNA at the restriction point and its positive correlation with the proliferative status of cultured mammary epithelial cells suggests a role of BRCA1 in control of the proliferative fate (Gudas et al., 1996) . The phosphorylation status of BRCA1 mirrors its expression pattern, becoming detectable at mid to late G1 phase, peaking in S phase and remaining high throughout M phase (Chen et al., 1996) . Two cellular proteins, designated BRCA1 interacting proteins (p64 BIP and p32 BIP), bind to a GST-BRCA1 (amino acids 1 -76) fusion protein in vitro (Wang et al., 1997) . Western blots of BIP complexes reveal binding of antibodies specific for cdc2, cdk2, cdk4, cyclin A, cyclin B1, cyclin D1, cyclin E and E2F-4, suggesting an association of BRCA1 with these proteins. BRCA1 is phosphorylated by kinases associated with cyclins D and A as well as by CDK2 in vitro (Chen et al., 1996) . Further, the splice variants BRCA1a and BRCA1b bind to GST fusion proteins of cyclin A, cyclin B1, cyclin D1, E2F-1 and E2F-4 in vitro (Wang et al., 1997) . Taken together, these results suggest that the phosphorylation status, and perhaps the activity of BRCA1 is regulated by cyclin/CDK complexes.
Growth Properties of Cells with Altered Levels of BRCA1
In view of the roles BRCA1 plays in DNA repair, transcriptional transactivation and cell cycle control, it is understandable that changes in the expression level of BRCA1 will modify its modes of interaction with its associated proteins and result in changes in cell growth properties. Most reports in this area are based on forced expression or reduction of BRCA1 mRNA in a limited number of cell lines and require substantiation by follow-up studies. Holt et al. (1996) report that over expression of fulllength BRCA1 in MCF-7 cells leads to a significant inhibition of cell growth, and an inhibition of tumor formation in nude mice. Conversely, overexpression of a BRCA1 variant lacking most of exon 11, and therefore missing nuclear localization signals and Rad51 binding site, in serum-depleted NIH3T3 cells or calcium ionophore treated MCF-7 cells results in an apoptotic response. Thus one role of BRCA1 may be the involvement in apoptotic control .
Expression of antisense BRCA1 mRNA in NIH3T3 cells results in a flattened phenotype, faster proliferation rate and a gain in ability to grow in both lowserum media and serum-free media as well as anchorage independent growth in soft agar. Subcutaneous injection of BRCA1 antisense expressing cells into nude mice results in tumor formation. Larson et al. (1997) transfected a vector with a BRCA1 gene fragment encoding the C-terminal residues 1293 -1863 into the non-tumorigenic human breast epithelial cell line 184A1. Transfected cells displayed a reduction in doubling time, a reduced dependence on mitogens such as EGF, and a loss of G 2 -M block by colchicine. Perhaps the expression of this construct, possibly in a dominant-negative manner, in the 184A1 cell line is responsible for the loss of a proper G 2 -M checkpoint control.
Possible Control of BRCA1 Levels by CpG Methylation and Ubiquitin-Proteosome
Investigation of the control of BRCA1 expression is a necessity to understand how it performs its biological roles. In particular, reports that BRCA1 levels are decreased in sporadic breast cancer mandates the elucidation of factors regulating BRCA1 expression. Other studies have found that BRCA1 mRNA expression levels are up to five-to ten-fold higher in mammary tissue from a normal individual than in mammary tissue from sporadic invasive breast cancer samples (Thompson et al., 1995; Sourvinos and Spandidos, 1998) . Vaurs-Barriere et al. (1998) report the loss of heterozygosity at the BRCA1 locus in some sporadic breast carcinomas, which could account for reduced expression. Evidence of allelic loss and low levels of BRCA1 expression is also cited by Ozcelik et al. (1998) , suggesting that sporadic breast cancer may at least in part arise from dysregulation of the BRCA1 gene.
The promoter region of BRCA1 contains a high proportion of CpG dinucleotides (Mancini et al., 1998) . Such CpG islands are potential transcriptional regulation sites due to the possible methylation of cytosines, which may then alter gene expression by preventing regulatory elements from binding to the promoter. Silencing of gene expression via DNA hypermethylation of regulatory regions has been documented in at least three tumor suppressor genes, namely retinoblastoma (Rb) (Ohtani-Fujita et al., 1993) , p16 (Merlo et al., 1995) and von Hippel-Lindau (VHL) (Herman et al., 1994) . Mancini et al. (1998) found two out of six breast carcinoma samples and two out of five ovarian carcinoma samples which displayed varying degrees of CpG methylation at a site upstream of and including exon 1a of BRCA1. Furthermore, one of these CpG sites was located within a putative cAMP-responsive element binding (CREB) site. Gel mobility shift assays using MCF-7 nuclear extracts and radiolabelled methylated or unmethylated double-stranded oligonucleotides showed a loss of protein binding to the methylated DNA, suggesting that the CREB site of BRCA1 is sensitive to DNA methylation. Methylation of the cAMP responsive enhancer/promoter sequence was known to abolish specific factor binding as well as transcriptional activation (Iguchi-Ariga and Schaffner, 1989) .
The BRCA1-associated protein 1 (BAP1) was discovered in a yeast two-hybrid screening as a novel protein which binds to the RING finger domain of BRCA1 (Jensen et al., 1998;  Table 1 ). BAP1 shows nuclear colocalization with BRCA1, and contains motifs and activities characteristic of a ubiquitin carboxy-terminal hydrolase, suggesting that the ubiquitin-proteasome pathway is a regulator of BRCA1 activity. The carboxy-terminus of BAP1 is hydrophilic and may form a helical, perhaps coiled-coil, structure. Disruption of this helical region by the mutation Leu691Pro abrogates the BAP1-BRCA1 interaction, suggesting that the coiled-coil domain of BAP1 is the region which interacts with the RING finger of BRCA1. The growth suppressive capability of overexpressed BRCA1 in MCF7 cells is augmented four-fold by the overexpression of BAP1. It is possible that BAP1 represents a novel tumor suppressor gene, as further supported by the discovery of a homozygous deletion of BAP1 in a lung carcinoma cell line (Jensen et al., 1998) .
Other Functional Interactions with BRCA1
The product of the c-Myc proto-oncogene binds BRCA1 in both yeast two-hybrid and in vitro experiments . This association can also be detected through co-immunoprecipitation in untransfected 293T cells (Table 1) , together suggesting that BRCA1 may affect the transcription activation function of c-Myc. Indeed, overexpression of BRCA1 negatively regulates Myc-mediated transcription, as demonstrated by reduced expression of luciferase reporters carrying Myc binding sites. BRCA1 was also shown to suppress cellular transformation induced by co-transfection of c-myc and H-ras in rat embryonic fibroblasts, perhaps through disruption of Myc-Max heterodimerization. These findings raise the possibility that BRCA1 may exert its tumor suppressing activity in part through an interference of the growth-stimulatory properties of c-Myc, and that loss of this negative regulation through a BRCA1 mutation may eventually lead to cellular transformation . Additionally, under certain conditions overexpression of c-Myc results in an apoptotic response; whether or not BRCA1 inhibits Myc-mediated apoptosis remains to be established.
A second protein recently discovered to interact with BRCA1 is the Breast Cancer Susceptibility Gene 2 (BRCA2) gene product (Chen et al., 1998) . The tumor suppressors BRCA1 and BRCA2 were previously shown to share similar properties, including the timing of expression (Rajan et al., 1996) , the phenotypes of knockout mice (Hakem et al., 1996; Gowen et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Suzuki et al., 1997) and an association with Rad51 (Scully et al., 1997a; Sharan et al., 1997) on meiotic chromosomes. Through co-immunoprecipitation and in vitro binding studies, Chen et al. (1998) demonstrated that a region of BRCA1 near the C-terminus can bind BRCA2. Furthermore, both BRCA1 and BRCA2 were found to colocalize in S phase nuclear foci. Upon treatment of late S phase cells with hydroxyurea, BRCA2, like BRCA1, Rad51 and BARD1, colocalized with PCNA (Chen et al., 1998; Scully et al., 1997b) , implicating BRCA2 in a possible multi-protein repair complex. Co-immunostaining of human spermatocytes also showed colocalization of BRCA1 and BRCA2 on developing synaptonemal complexes, suggesting a role for these proteins in homologous recombination (Chen et al., 1998) .
The BRCA1 protein has also been localized to another multi-enzyme apparatus: the centrosome (Hsu and White, 1998) . BRCA1 is not alone in this regard, as many cell cycle regulators, including p53 and Rb, have been identified as centrosome-associating proteins. In COS-7 cells, colocalization of BRCA1 and ␥-tubulin at mitotic centrosomes was apparent from prometaphase to early anaphase, diminishing through late anaphase. BRCA1 was also detected in centrosome-enriched fractions from COS-7 and MCF7 cells, and co-immunoprecipitation experiments confirmed an association between BRCA1 and ␥-tubulin. The significance of centrosome localization for BRCA1 during mitosis is unknown; it may be that BRCA1 is involved in microtubule nucleation, or perhaps is passively attaining equal distribution to daughter cells through association with centrosomes (Hsu and White, 1998) . It will be of interest to see which of the many BRCA1-associated proteins accompany BRCA1 in this respect.
Concluding Remarks
Mutations in BRCA1 predispose women to breast and ovarian cancers which is the end-point of a malfunction of the BRCA1 protein. For a protein of considerable size, BRCA1 has yet to be associated with an enzymatic function in which the protein itself performs the catalytic task. Instead, an increasing number of reports have demonstrated that BRCA1 binds to and interacts with a number of known or new regulatory proteins (Table 1) . Available evidence suggests that BRCA1 also participates in the known functions of these cellular proteins, e.g., DNA repair, transactivation, and cell cycle control, etc. In the future, it is likely that additional proteins will be found binding to BRCA1 through which other functions will be assigned.
BRCA1 is unlikely to be a passive, static carrier for cell regulatory proteins. The formation of nuclear dots composed of BRCA1, BARD1, BRCA2 and Rad51 proteins during S phase, and their dispersion upon DNA damage and relocation to PCNA containing complexes, suggests that BRCA1 functions as an active vehicle for selected cellular proteins to converge on. This 'converging vehicle' concept implies that the molecular nature of the BRCA1 protein selects the binding of a subset of important cellular proteins, and that the resulting BRCA1-associated complexes can translocate to cellular sites to perform their functions. It also suggests that the efficacy and accuracy of these cellular functions could be modulated upon binding to BRCA1. The possibility of new, as yet undescribed, modes of action generated by the binding of more than one cellular protein to BRCA1 cannot be ignored. It is also obvious that mutations in BRCA1 would affect the composition of the BRCA1-associated complexes on which dysregulation of cellular functions with the eventual development of malignancy is expected. Finally, the tissue specificity of the BRCA1-associated tumors is also predicted to be mediated through the altered expression of a factor from breast, ovarian, or even prostate tumors, capable of binding to and interacting with BRCA1 and its various associated proteins.
